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The regulatory mechanisms of tumor necrosis factor a (TNF-a) production,
as well as those controlling the differential TNF-a sensitivity of normal and
malignant cells, appear complex and are still poorly understood. Like other
cytokines, TNF-a confers its signal to target cells via binding to specific cell
surface membrane receptors (1-3). Expression ofTNF-a membrane receptors is
necessary, but not sufficient to determine responsiveness of a given target cell
(1, 3, 4). With increasing knowledge on the diversity of cellular responses to
TNF (for review see 5 and 6), the question arises, by which mechanisms such
diverse TNF responses are controlled. Control mechanisms operating at a
postreceptor level (6), as well as receptor heterogeneity (7), may contribute to
the differential responsepatternofdistinct cell types. Moreover, there are several
examples that the magnitude of a particular biological response to a given
cytokine isproportional to the quantityofligand receptor interactions, indicating
that the number of expressed membrane receptors is a critical parameter in
determination ofcellular sensitivity to the cytokine in question (6, 8, 9). While
it was so far assumed that there is constitutive expression of TNF receptors in
most tumor cells (3, 4), we recently have shown that, in normal peripheral
lymphocytes, positive and negative regulatory mechanisms control membrane
expression ofTNF receptors. Thus, TNF receptors are reversibly induced in T
cells and expressed in a stimulus-dependent manner (10). Moreover, TNF
receptors in activated T cells can be rapidly modulated by activators ofprotein
kinase C, resulting in loss ofTNF-binding capacity (11).
We here demonstrate that protein kinase C-mediated downregulation ofTNF-
binding capacity is a general mechanism effective in both malignant and normal
cells of various tissues. The data show that loss of TNF-binding capacity is most
likely due to a drastic change in affinity rather than internalization or shedding
of TNF receptor molecules. As downregulation of TNF-binding capacity was
associated with a decrease in TNFsensitivity, ourdata suggest thatprotein kinase
C is involved in the control ofTNF responsiveness.
This work was supported by Stiftung Volkswagenwerk and Deutsche Krebshilfe. R. Unglaub and B.
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Materials and Methods
Materials. Phorbol myristate acetate (PMA) and oleyl acetyl glycerol (OAG)' were
from Sigma Chemical Co., Heidelberg, Federal Republic of Germany. 1-(isoquinolinesul-
fonyl)-2-methyl-piperazine (H7) and N-(2-guanidinoethyl)-5-iosquinolinesulfonamide (HA
1004) were from Seikagaku Kogyo Co., Tokyo, Japan.
Cells and Culture Conditions.
￿
The human leukemic cell lines U 937 (histiocytic) and K
562 (erythroleukemia), as well as the colon adenocarcinoma line Colo 205 were obtained
from American Type Culture Collection, Rockville, MD. Normal peripheral T lympho-
cytes were purified, stimulated with matrix-bound anti-T cell receptor antibody, and
cultured in 10 ng/ml of purified recombinant IL-2 for 5-10 d before use as described
(12).
Cytokines.
￿
Highly purified (>99%) recombinant human TNF-a as well as IFN-,y (Ge-
nentech, South San Francisco, CA) were kindly provided by Dr. G. Adolf, Boehringer
Ingelheim, Vienna, Austria. The specific activity of TNF-a, as determined by cytotoxicity
assay on murine L 929 cells, was 5 X 107 U/mg. Radioiodination of TNF-a to a specific
radioactivity of ^-40 uCi/Ag without significant loss of bioactivity was performed as
described (3). Human recombinant IL-2 with a purity of >99.5% was kindly provided by
Dr. M. Wrann, Sandoz Forschungsinstitut, Vienna, Austria.
Assay Systems. Binding assay with '251-TNF-a was performed as described (3, 10).
Measurements were usually performed in triplicates and included controls for unspecific
binding of the ligand in the presence of a 200-fold excess of unlabelled TNF-a. Bioassay
for TNF-a using murine fibrosarcoma L 929 cells was performed in flat-bottom microtiter
plates (six replicates) as described (13).
Determination of Internalized TNF-a.
￿
To determine the amount of internalized 1251-
TNF-a, membrane-associated ligand was removed by a pH 3 wash over a three-step
gradient. All steps were performed at 0-4°C. Cells were divided into two aliquots (1-2 X
106 cells in 0.5 ml) and one aliquot was layered on top of a discontinuous gradient
consisting of the following three solutions: (a) 0.5 ml of culture medium supplemented
with 20% Ficoll; (b) 3 ml of 100 mM NaCI, 50 mM glycine/HCI, pH 3.0, supplemented
with 10% Ficoll ; and (c) 0.5 ml of culture medium supplemented with 5% Ficoll. The
second cell aliquot was used for determination oftotal amount ofcell-associated '251-TNF-
a, and was layered on top of a similar Ficoll gradient consisting of PBS (pH 7.3)
supplemented with 10% Ficoll in the second layer. The cells were centrifuged for 10 min
at 50 g, the solution was carefully aspirated, and cells were transferred into counting vials
to determine radioactivity. Under these conditions ofpH 3 wash, >90% ofthe membrane-
receptor-bound 125I-TNF-a can be dissociated from the cells.
Preparation of Cell Membranes.
￿
All manipulations were performed at 4 °C (buffer A:
125 mM sucrose, 7 .5 mM Tris/HCI, pH 7 .4, 2 mM EDTA, 2 mM EGTA, and 1 mM
PMSF; buffer B: 100 mM Tris/HCI, pH 7.4, 10 mM CaCl2, 10 MM MgC12, 1 mM PMSF,
and 2% FCS). Cells were harvested, washed once in buffer A, and allowed to swell for 20
min in buffer A at 108 cells/mi. They were subjected to homogenization in a glass/glass
potter with 50 gentle strokes at 1,000 rpm. The homogenate was diluted with an equal
volume of buffer A, and intact cells as well as nuclei were removed by centrifugation for
10 min at 50 g. The pellet was washed with an additional volume of buffer A, and
membranes were obtained from the combined supernatants by centrifugation for 15 min
at 12,000 g and washed twice with buffer B.
Results
The effect of the phorbol ester PMA on TNF-binding capacity was investigated
on tumor cell lines derived from various tissues. As shown in Table 1, a significant
reduction of TNF binding was observed in all tumor cell lines after incubation
for 20 min with PMA. Normal diploid fibroblasts, as well as normal activated T
'Abbreviations used in this paper: CHX, cycloheximide; H7, 1-(isoquinolinesulfonyl)-2-methyl-
piperazine; HA 1004, N-(2-guanidinoethyl)-5-isoquinolinesulfonamide ; OAG, oleyl acetyl glycerol.1790
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TABLE I
TNFReceptor Downregulation Mediated byPMA Is Not Tissue-specificand Is Antagonized by
Protein Kinase C Inhibitors
Cells (6 x 106 cells/ml)were incubated for20 min at 22°C with PMAat the indicated concentrations .
Thereafter, the cells were washed twiceand 121I-TNF-a-binding capacity wasdetermined in compar-
ison with untreated cells . To determine the effect of protein kinase inhibitors H7 andHA 1004,
respectively, T cells were preincubated with 50 uM of the respective agent before the addition of
PMA. All cell lines were derived from American Type Culture Collection lines .
FIGURE 1 .
￿
PMA does not downregulate TNF-a-binding capacity of
isolated plasma membranes . K 562 cell membranes were prepared as
described in Materialsand Methods . TNF-a-binding capacity of mem-
brane equivalents from 4 x 106 cells (M) wascompared with that of 2
x 10 6 K562 cells (N) before and after treatment with 100ng/ml PMA
for20 min at room temperature . 12-1I-TNF-a-bindingexperiments with
membranes were performed in buffer B. Centrifugation steps were
carried out at 12,000 g .
cells showed a similar response (Table I) . PMA treatment of isolated cell mem-
branes did not affect TNF-binding capacity, indicating that receptor modulation
was not due to direct interaction ofPMA with TNF-receptor molecules (Fig . 1) .
As shown previously (11), pretreatment of T cells with the protein kinase
inhibitor H7 reduced the loss ofTNF-a-binding capacity of PMA-treatedT cells
(Table I) . In contrast, pretreatment with protein kinase inhibitor HA 1004 did
not prevent downregulation (Table I) . Both substances are strong inhibitors for
a variety of protein kinases, however, the affinity of HA 1004 for protein kinase
C is about sevenfold lower as compared with H7 (14) . These data, therefore,
strengthen the view that protein kinase C is the mediator of PMA-induced
downregulation ofTNF-a-binding capacity .
To address questions concerning the mechanisms of TNF receptor down-
regulation, the following experiments were performed largely with the leukemic
PMA Residual
Cell line Origin concen- specific 12-11-TNF-a tration binding
ng/ml %
HL 60 Myeloid leukemia 10 46
K 562 Myeloid leukemia 100 22
U 937 Myeloid leukemia 100 17
HuT 78 T lymphoma 10 9
Colo 205 Colon carcinoma 10 3
WiDR Colon carcinoma 10 22
PA 1 Teratocarcinoma 10 48
CCD 18 Diploid fibroblasts 10 37
T cells Normal PBL 10 10
T cells PK inhibitorH7 5 44
T cells PK inhibitorHA 1004 5 16
T cells None 5 14UNGLAUB ET AL.
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FIGURE 2.
￿
Kinetics of reappearance ofTNF-a-bind-
ing capacity after treatment of cells with OAG or
tryp psin. Cells were incubated with 100 jAM OAG at
10 cells/ml at 37°C. At the times indicated, aliquots
of 6 x 106 cells were taken, washed once, and
125I-
TNF-a-binding capacity wasdetermined (three repli-
cates for each specific and unspecific binding). After
30 min of OAG treatment thecells were collected by
centrifugation, washed once to continue cell culture
in the absence of OAG (arrow). At the same time the
culture of trypsin-treated cellswasset up forcompar-
ison (0.2%wt/vol trypsinat 37°C for15 min). Specific 125I-TNF-a-binding is given in percent of untreated
controls, which remained constant over the time of
the experiment (T cells: 11,800 ± 700; U 937 cells;
8,700 ± 650 cpm).
FIGURE 3. Influence of CHX treatment on TNF
receptor expression. U 937 cells were preincubated
for 30 min with I0,ug/ml CHX. Aliquots were either
left untreated or treated with OAG and trypsin, re-
spectively, as described in Fig. 2. Thereafter, cells
were washed and again supplemented with 10 jug/ml
CHX andkept at 37°C fortheindicatedtimes. At the
indicated times, 6 x 106 cells from each group were
taken to determine TNF-a-binding capacity. Specific 1251-TNF-a binding is given in percent of untreated
cells (11,200 ± 750 cpm).
cell lines K 562 and U937 as well as with normal activated Tcells, which express
high numbers of TNF receptors and respond to TNF-a (3, 10, 15, 16). PMA-
induced TNF receptor downregulation lasted for more than 12 h, even when
the cells had been washed after PMA treatment (data not shown). In contrast,
lossofTNF-bindingcapacity induced by themembranepermeableprotein kinase
C activator OAG was fully reversible. After removal of OAG, half-maximal
binding capacity ofboth U937 cells and ofactivated T cellswas recovered within
^"3 h ofincubation at 37°C (Fig. 2). Scatchard analyses of U 937 cells at different
times after OAG treatment indicated an apparent loss of high-affinity TNF
receptors, with no evidence for the appearance of a low-affinity set of TNF
receptors, even when 1251-TNF-a concentrations up to 1 Ag/ml had been used in
TNF-a binding assays (data not shown). Recovery of TNF-binding after OAG
treatment occurred with similar kinetics, as upon complete removal of receptors
by trypsinisation (Fig. 2). Blocking ofprotein synthesiswith cycloheximide (CHX)
revealed a half-life of TNF receptors of ^-2 h in unstimulated U937 cells (Fig.
3). CHX treatment totally abolished the reexpression of TNF receptors, inde-
pendent ofwhetherreceptorshad been removedbytrypsin treatment or whether
TNF-a-binding capacity had been downreguaated by OAG treatment (Fig. 3).
These data indicate that (a) the internal pool of TNF receptor proteins is
neglectable and that (b) recovery ofTNF-a-binding capacity upon protein kinase
C-mediated downregulation requires de novo protein synthesis.
We then investigated whether protein kinase C-mediated TNF receptor
modulation affects internalization of ligand/receptor complexes. Fig. 4 shows
the kinetics of dissociation and internalization of '251-TNF-a of untreated and
PMA-treated U 937 cells. The data indicate that in the absence of PMA ^-25%1792
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FIGURE 4 .
￿
PMA treatment prevents internaliza-
tion and increases dissociation of TNF-a-receptor
complexes. U 937 cells were incubated at0°Cwith
20 ng/ml of 1Y5í-TNF-a for 1 h to saturate cell
surface TNF receptors. Then cells were washed
twiceand incubated at 37°C without or with 100
ng/mlPMA to follow the rate of internalization
and dissociation. At the times indicated, aliquots
of6 x 10 6 cells were takenandimmediately cooled
down by the addition of excess ice cold PBS sup-
plemented with 2% FCS and 0.02% sodium azide .
After collection of the cells by centrifugation, ali
quots were prepared to determine the total amount of cell-bound radioactivity (centrifugation over
apH 7 gradient) as well as internalized 1Y5í-TNF-a (centrifugation over apH 3 gradient) as described
in Material and Methods . Unspecific binding was similar in all groups (<12%), and was subtracted .
100% of specificTNF-abinding represents 12,400 cpm .
FIGURE 5 . Time and temperature dependence of
OAG-induced downregulation of TNF-a-binding ca-
pacity . U 937 cells were treated at the indicated tem-
peratures with 100 uM OAG. At the times indicated,
TNF-a-binding capacity wasdetermined from aliquots
of the cells, using 20 ng/ml 1Y5í-TNF-a.
of the receptor-bound TNF-a is internalized within 40 min at 37°C . Upon
incubation in the presence of PMA, however, the vast majority o£ prebound
TNF-a dissociates, while internalization is abolished (Fig. 4) . Moreover, at
temperatures below 17°C, where membrane fluidity is low (17), internalization
of TNF-a is not detectable during a I-h incubation period (data not shown) .
However, OAG treatment of U937 cells at 14°C as well as 0°C still produced a
reduction of TNF-a-binding capacity, although the kinetics of receptor modu-
lation were different at 37, 14, and 0°C, respectively (Fig . 5) . Half-maximal
reduction was achieved after 3 min at 37"C and after ^-30 min at 14'C . Only
partial decrease of TNF-a-binding capacity was noted at 0°C during a 5-h
incubation (data not shown) . These data show that protein kinase C-mediated
downregulation of TNF-binding capacity is neither due to internalization nor
due to shedding of receptor molecules .
As the magnitude of TNF-a response, e.g ., cytostasis of U937 cells and HLA-
A,B,C expression in K562 cells, is proportional to the number of ligand/receptor
interactions (Fig. 6), we addressed the question whether downregulation ofTNF-
a-binding capacity would result in a respective change in TNF-a responsiveness .
In fact, a clear modulation of TNF-a responsiveness was observed in distinct
assay systems . In a TNF cytotoxicity assay with actinomycin D-treated L 929
cells, 10-20-fold higher concentrations of TNF-a were necessary to reach the
same cytotoxic effects in the presence of 10 ng/ml ofPMA (not shown) or 100
,uM OAG (Fig . 7) . At these concentrations, neither OAG nor PMA influenced
cell viability by themselves . As in this assay system, a 2-h pulse treatment with
TNF-a was sufficient to mediate a strong cytotoxic effect, itwas possible to studyFIGURE 6. Correlation between the number of
ligand-receptor interactions and the resulting bio-
logical TNF-a response . Cells were cultured for
48 h with various concentrations ofTNF-a. There-
after, HLA-A,B,C expression in K 562 cells was
determined using an EpicsCcytofluorograph (16),
and cytostatic activity of TNF-a towards U 937
cells was determined by a standard ['H]thymidine
incorporation assay as described (3) . The number
too
￿
19&
￿
10400
￿
of occupied TNF-a receptors was calculated for
nwneaa TNFa receptors occupied
￿
each TNF-a concentration on the basis of a disso-
ciation constant of Kd = 1 .5 X 10- ' ° M (3), using the formula : percent occupied receptors = 100 X
(concentration)/(concentration +Kd). Biologic response is given in percent o£ the maximally achiev-
able response for each cell line at saturating concentrations of TNF-a (100 ng/ml) .
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FIGURE 7 .
￿
OAG-mediated reduction ofTNF sensitivity is re-
versible . L929 cells were treated with 100 kM OAG for 30 min
at room temperature. Thereafter, the cells were washed twice,
and serial dilutions of TNF-a were added either in the absence
(Q) or presence (") of 100 uM final concentration of OAG . In
addition, control cultures were setup with untreatedL cells (/) .
All three groups were maintained in TNF-a for 2 h at 37°C,
washed once to remove unbound TNF-a, and cell culture was
continued for 22 h in the presence of actinomycin D (1 ug/ml) .
FIGURE 8. Inhibition of TNF-
a-mediated enhancement of
HLA-DR expression in parallel
with downregulation of TNF-a-
binding capacity in PMA-treated
Colo 205 cells . Colo 205 cells (107
cells/group) were cultured with
the indicated substances at the fol-
lowing concentrations : PMA, 10
ng/ml ; TNF-a, 10 ng/ml; IFN-y,
0.01 ng/ml. PMA was added 30
min before addition of cytokines .
After 2 d of culture, in each group HLA-DR expression was determined by fluorocytometry using
an FITC-labeled monoclonal antibody L 243 as described (I6) . In parallel, specific '251-TNF-a
capacity was determined in all those groups, which were not treated with TNF-a in the preceding
culture, using 20 ng/ml of '25I-TNF-a .
whether TNF unresponsiveness is restricted to the period of TNF-a-binding
deficiency, which can be transiently induced by pulse treatment of cells with
OAG (Fig . 2) . L929 cells were treated for 30 min with 100 p.M OAG to obtain
maximum downregulation of TNF-a-binding capacity (see Fig. 2) . Thereafter,
OAG was removed by two washing steps and the cells were then incubated with
TNF-a for 2 h . Under these conditions, reduction ofTNF-a sensitivity was only
2-fold, as compared with the 16-fold reduction when OAG was continuously
present during the 2-h TNF-a treatment of L cells (Fig . 7) . Thus, upon transient
stimulation of protein kinase C, allowing rapid reappearance of TNF-binding
capacity, a parallel reappearance ofTNF-ce sensitivity is observed .
PMA also strongly antagonized with TNF-mediated enhancement of antigen
expression in various tumor cell lines, as well as in normal T cells. An example
is shown in Fig . 8, where the capacity ofTNF-a to enhance IFN-y-induced HLA-
DR expression in Colo 205 cells (15, 16) was used as a model to study the1794
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influence of protein kinase C activation on TNF receptor expression and TNF-
a responsiveness. In accordance with earlier results (15, 16), TNF-a exerted
strong synergistic activity, resulting in a roughly sevenfold increase in IFN-y-
induced HLA-DR antigen expression. In the presence of PMA, the TNF-a-
mediated enhancement of HLA-DR expression in Colo-205 cells was greatly
diminished . In contrast, PMA by itself and in combination with IFN-'r had a
slight stimulatory effect on HLA-DR expression in these cells. The reduced
TNF-a sensitivity of Colo 205 cells corresponded with a reduced TNF-binding
capacity, determined in parallel (Fig. 8).
Discussion
We have shown here that intracellular control mechanisms ofTNF-a sensitivity
exist in both normal and malignant human cells, which are linked to protein
kinase C and enable the cell to rapidly downregulate TNF-binding capacity,
thereby increasing resistance to TNF-a. While cells derived from various tissues
show, with respect to modulation of TNF-a-binding capacity, differential sensi-
tivity to protein kinase C activators (Table 1), the basic finding of downregulation
is apparently a general phenomenon. We have previously described that in
activated T cells, only those activators of protein kinase C that are membrane
permeable were able to modulate TNF-binding capacity (11) . In extension of
these results, we have here excluded the possibility that protein kinase C activa-
tors might directly interact with the ligand-binding site of TNF receptors, as
PMA itself has no effect on TNF-binding capacity of isolated cell membranes
(Fig. 1). Clearly some cytosolic compounds are necessary to confer PMA-induced
reduction of TNF-binding capacity. The differential capacity of the selective
inhibitors of protein kinases H7 and HA 1004, respectively, to interfere with
PMA-induced downregulation further supports the view that protein kinase C is
directly involved in this process (Table 1).
TNF-receptor modulation is an extremely rapid event (11) (Fig. 2), which
already suggested that neither internalization nor shedding of receptor molecules
could account for this phenomenon. Indeed, the data presented in Fig. 4 show
that internalization of preformed TNF-receptor complexes is not enhanced by
PMA treatment. Quite in contrast, in the presence of PMA, internalization of
TNF-a is strongly reduced, probably because TNF-receptor complexes more
rapidly dissociate compared with the untreated control. These results indicate
that loss of the binding capacity of the receptor, triggered by PMA, and
internalization of the TNF-a-receptor complex are independent reactions.
At 14°C, OAG treatment produces a reduction in TNF-a binding comparable
to that at 37°C (Fig. 5). At this temperature, cellular membranes are still in a
frozen state, preventing both internalization and shedding. Accordingly, as
receptor molecules must still be present in the cell membrane, downregulation
of TNF-a-binding capacity at 14 ° C must be explained by a change in ligand
affinity of the majority of expressed receptor molecules. As in binding assays
with PMA- or OAG-treated cells using a concentration range up to 5 x 10-8 M,
no specific TNF-a binding was obtained, aside from that by the few remaining
high-affinity receptors, affinity of modulated TNF receptors must have changed
drastically (? 100-fold), thereby causing functional inactivation. This processUNGLAUB ET AL.
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appears irreversible, because recovery of TNF-a-binding capacity after down-
regulation is dependent on de novo protein synthesis (Fig. 3). Further, kinetics
of reappearance of TNF-a-binding capacity after OAG treatment is comparable
with that of cells, where cell-surface receptor proteins had been removed by
trypsinization (Fig. 2), indicating that both processes simply reflect normal
receptor turnover. The half-life of TNF receptors of -2 h, found in CHX-
treated U 937 cells (Fig. 3) is consistent with this interpretation.
As to the molecular mechanism by which protein kinase C stimulation leads to
modulation ofTNF-binding capacity, our data suggest a direct phosphorylation
of the receptor protein(s) at its cytoplasmic site. Such a mechanism has been
shown to affect the function of other membrane receptor proteins: phosphoryl-
ation of receptor proteins by protein kinase C can either lead to enhanced
internalization (transferrin receptors), result in achange in ligand affinity (insulin
and epidermal growth factor receptors), or change the potential tyrosine kinase
activity of the receptor protein itself (insulin receptors) (for review see 18).
There is general agreement that expression of TNF receptors is a prerequisite
for biological responses to TNF-a, as cells, which, a priori, lack TNF receptors
(3, 19), or have completely lost binding capacity upon CHX treatment (20), are
TNF resistant. Regulation of receptor expression as a potential mechanism for
a quantitative regulation of TNF responses was suggested from the finding that
the magnitude of a given TNF-a response is proportional to the number of
receptor-ligand interactions (Fig. 6). Thus, IFN-'Y-mediated upregulation of
TNF-a receptors may contribute to enhancement of TNF responses (21), al-
though this effect by itself is not sufficient to explain synergism of the two
cytokines (6). However, the data presented here show direct correlation between
TNF-a-binding capacity and TNF-a sensitivity. PMA, which downregulates
TNF-a-binding capacity for prolonged periods of time, was able to strongly
interfere with various TNF-a actions, e.g., cytotoxicity on L929 cells (data not
shown) and enhancement of HLA-DR expression in Colo 205 cells (Fig. 8).
Moreover, using the rapidly metabolized glycerol derivative OAG for transient
stimulation of protein kinase C, we could show that reexpression of TNF-a-
binding capacity is accompanied with reversion of TNF-insensitive cells to their
TNF-sensitive phenotype (Fig. 7). These data, therefore, suggest that induction
ofTNF-a resistance by activators of protein kinase C is effective at the level of
TNF receptor expression.
Summary
The regulatory action ofactivators for protein kinase C on the specific binding
capacity for recombinant human tumor necrosis factor a (TNF-a) was studied
on various human cell lines. Phorbol myristate acetate (PMA) and oleyl acetyl
glycerol (OAG) both are able to rapidly downregulate TNF-binding capacity of
normal and malignant cells derived from various tissues. As PMA treatment did
not enhance internalization of TNF-a-receptor complexes at 37°C, and since
OAG was able to downregulate TNF-binding capacity under conditions where
internalization and shedding of receptor protein are prevented, we conclude
that protein kinase C controls ligand affinity of the TNF-receptor protein,
possibly via direct phosphorylation. Protein kinase C triggered downregulation1796
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of TNF-a-binding capacity concomitantly resulted in reduction of TNF-a sensi-
tivity, as revealed from decreased cytotoxic action of TNF-a on L 929 cells and
from inhibition of TNF-a-mediated enhancement of HLA class II antigen
expression in Colo 205 cells. Restoration of TNF-binding capacity upon abro-
gation of protein kinase C stimulation leads to full recovery of TNF responsive-
ness, further supporting the close linkage of TNF-receptor expression and TNF
sensitivity. These data suggest that regulation ofTNF-binding capacity by protein
kinase C is one of the cellular control mechanisms of TNF responsiveness.
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